MedTrace Logo

Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults

NCT01708720 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2014-02-21

No results posted yet for this study

Summary

The purpose of this trial is to determine whether the new inactivated polio vaccine that is based on attenuated poliovirus strains is safe and to evaluate the immune response in healthy adults.

Conditions

  • Poliomyelitis

Interventions

DRUG

IPV

DRUG

Sabin-IPV

DRUG

Adjuvanted Sabin-IPV

Sponsors & Collaborators

Principal Investigators

  • Pauline Verdijk, PhD · Institute for Public Health and the Environment

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2011-09-30
Completion
2012-02-29

Countries

  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01708720 on ClinicalTrials.gov